Royalty Pharma plc

NasdaqGS RPRX

Royalty Pharma plc Goodwill for the quarter ending September 30, 2024: USD 0.00

Royalty Pharma plc Goodwill is USD 0.00 for the quarter ending September 30, 2024, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.
  • Royalty Pharma plc Goodwill for the quarter ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
  • Royalty Pharma plc Goodwill for the quarter ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
  • Royalty Pharma plc Goodwill for the quarter ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
  • Royalty Pharma plc Goodwill for the quarter ending September 30, 2020 was USD 0.00.
Key data
Date Goodwill Total Assets Current Liabilities Total Non-Current Liabilities
Market news
Loading...
SV Wall Street
NasdaqGS: RPRX

Royalty Pharma plc

CEO Mr. Pablo Gerardo Legorreta
IPO Date June 16, 2020
Location United States
Headquarters 110 East 59th Street
Employees 75
Sector Health Care
Industries
Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Similar companies

IKNA

Ikena Oncology, Inc.

USD 1.50

1.35%

PRME

Prime Medicine, Inc.

USD 2.75

-2.83%

ADPT

Adaptive Biotechnologies Corporation

USD 7.71

-1.78%

MDGL

Madrigal Pharmaceuticals, Inc.

USD 326.33

-0.31%

AKRO

Akero Therapeutics, Inc.

USD 54.00

4.92%

DAWN

Day One Biopharmaceuticals, Inc.

USD 13.01

-1.51%

IOVA

Iovance Biotherapeutics, Inc.

USD 6.07

-1.94%

APLS

Apellis Pharmaceuticals, Inc.

USD 29.47

0.65%

DNA

Ginkgo Bioworks Holdings, Inc.

USD 12.25

-0.24%

ASND

Ascendis Pharma A/S

USD 127.55

-1.41%

BPMC

Blueprint Medicines Corporation

USD 114.32

-0.13%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.46

0.29%

StockViz Staff

January 30, 2025

Any question? Send us an email